Abstract Background -The optimal particle size of a P2 agonist or anticholinergic aerosol in patients with severe airflow obstruction is unknown. Methods -Seven stable patients with a mean forced expiratory volume in one second (FEV1) of 37.9% of the predicted value inhaled three types of monodisperse salbutamol and ipratropium bromide aerosols with particle sizes of 1.5 gm, 2.8 rtm, and 5 gm, respectively, and a placebo aerosol. The volunteers inhaled 20 ftg salbutamol and 8 ftg ipratropium bromide, after which lung function changes were determined and analysed with repeated measurements analysis of variance (ANOVA). Results -Greater improvements in FEV1, specific airway conductance (sGaw) and maximum expiratory flow at 75%150% of the forced vital capacity (MEF75/50) were induced by the 2.8 gm aerosol than by the other particle sizes. Conclusions -In patients with severe airflow obstruction the particle size of choice for a 2 agonist or anticholinergic aerosol should be approximately 3 ftm.
the greatest bronchodilatation. 4 To reach the smaller airways in such cases it may be necessary for the particle size of the inhaled aerosol to be decreased. In patients with severe airflow obstruction, aerosols with a smaller particle size may be more suitable. We therefore carried out experiments to determine the most suitable particle size for bronchodilator aerosols in patients with severe airflow obstruction.
Methods

PATIENTS
Eight patients (six men) started the trial but one dropped out for personal reasons. The mean (SD) age of the remaining seven was 55 (4) years, and the mean forced expiratory volume in one second (FEVI) was 37.9 (7. 3)% of the predicted value. In all patients a more than 15% increase in baseline FEV1 after inhalation of 200 jg salbutamol had been measured just before the trial. None of the patients was smokers. All used inhaled corticosteroids and none used disodium cromoglycate or oral antiasthma medications. Their regular medication other than corticosteroids was discontinued 6-8 hours before the start of the trial, and long acting 12 agonists were stopped 15 hours before the trial. All patients gave their written consent before entry into the study which was approved by the hospital ethics committee.
Accepted for publication 26 April 1996 In two previous publications we have reported on the optimal particle size of P2 agonist and anticholinergic aerosols.' 2 differences due to particle size of the aerosol, type of drug, and interaction between drug and aerosol size were determined using repeated measurements analysis of variance (ANOVA).7 A significant interaction, in this case, means that the difference between salbutamol and ipratropium bromide is not constant and depends on the particle size of the aerosol administered. When a statistically significant change was observed, the within group mean sum of squares was used to calculate the least significant difference. In all calculations a p value of < 0.05 was considered to be significant.
Results
All patients completed the study without noticeable side effects. No significant change was measured in any of the lung function parameters during the inhalation of placebo, nor were any significant differences seen between the bronchodilator responses of salbutamol and ipratropium bromide. Comparing identical particle sizes, there were no significant differences between salbutamol and ipratropium bromide. Significant differences were found in FEVy (p < 0.001), MEF75 (p = 0.02), MEF50 (P < 0.001), and sGaw (p = 0.01) with different particle sizes (fig 1, table 1 ). In table 2 the improvements in various lung function parameters after administration of 20 jg salbutamol and 8 jg ipratropium bromide, respectively, as 2.8 pm aerosols are given.
Discussion
In patients with severe airflow obstruction the particle size of choice for an aerosol is approximately 3 jim, both for ipratropium bromide and salbutamol. These results are comparable to our earlier findings with salbutamol and ipratropium bromide in patients with mild asthma in whom the greatest bronchodilatation was elicited by aerosols with an MMAD of < 2.8 jim.' 2 We believe that these findings are explained by the filtering characteristics of the extrathoracic/upper airways. Large particles are filtered out quickly in the central airways due to a high impaction probability. Only small particles will escape deposition in the extrathoracic/upper airway.3 The dose of inhaled drugs in the lungs or lower airways therefore depends on the filter characteristics of the extrathoracic/upper airways. Due to the fact that particles of < 2.8 jim MMAD pass ipratropium bromide dose delivered through a metered dose inhaler. We do not know the relative efficacy of our formulations compared with metered dose inhalers because this study was not set up as a direct comparison. The prestudy check of the patients, however, included measurement of the reversibility after 200 jg salbutamol via a metered dose inhaler and it was found that the mean (SD) improvement in FEV, was 7.6 (2.7)% compared with 8.5 (7)% after 20 jg salbutamol as a 2.8 jm aerosol. We therefore feel that it is possible to induce clinically significant bronchodilatation using low dosages of correctly formulated bronchodilators.
We conclude that, in patients with severe airflow obstruction, the most suitable particle size of a 2 agonist and anticholinergic aerosol is approximately 3 jm. Significant bronchodilatation is obtainable with 10% of standard dosages using metered dose inhalers. 
